Osamu Kanai

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A

0Author DataRank · unranked

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody”.

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

Thoracic Cancer(2020)10.1111/1759-7714.13241

N/A

3.0DataRank · unranked

46 citations

Yuki Yamamoto, Osamu Kanai, Misato Okamura, Masayuki Hashimoto, Koichi Nakatani +3 more

Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases

Cancer Chemotherapy and Pharmacology(2018)10.1007/s00280-018-3585-9

N/A

0.680DataRank · unranked

92 citations

Naohiro Uchida, Osamu Kanai, Misato Okamura, Koichi Nakatani, Tadashi Mio +1 more